Taksta

Taksta (previously CEM-102) is a front-loaded oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).[1]

Clinical trials

Jan 2010: Taksta has completed enrollment in a Phase 2 trial (due to run until March 2010) and is preparing for Phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with Linezolid). [2]

Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a Phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.[3]

Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.[4]

Dec 2015: Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections. (2015) [5]

Nov 2016: Cempra completes Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections. Results remain pending. (2016) [6]

Feb 2017: Cempra achieves the primary endpoint of a 10% non-inferiority margin. The microbiological success in each ME population with methicillin-resistant S. aureus (MRSA) infection is 100 percent (99/99) at both the EOT and PTE visits. (2017) [7]

See also

  • Fusidic acid, licensed for some decades outside the US and is in clinical development in the U.S.

References

  1. ↑ "Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs TAKSTA(TM) and CEM-101".
  2. ↑ "Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections". 15 April 2019. {{cite journal}}: Cite journal requires |journal= (help)
  3. ↑ Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). "A randomized, double-blind Phase 2 study comparing the efficacy and safeety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections." Clinical Infectious Diseases 52(Supplement 7):S520-S226.
  4. ↑ Wolfe CR. (2011) "Case report: treatment of chronic osteomyelitis." Clinical Infectious Diseases 52(Supplement 7):S538-S541.
  5. ↑ Cempra Press Release. Cempra Company http://investor.cempra.com/releasedetail.cfm?releaseid=946010. Retrieved 17 December 2016. {{cite web}}: Missing or empty |title= (help)
  6. ↑ "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections". ClinicalTrials.gov. FDA. Retrieved 17 December 2016.
  7. ↑ "Cempra's Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI". Cempra.com. Cempra. Retrieved 4 April 2017.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.